Cargando…

A study of quality assessment in SARS-CoV-2 pathogen nucleic acid amplification tests performance; from the results of external quality assessment survey of clinical laboratories in the Tokyo Metropolitan Government external quality assessment program in 2020

INTRODUCTION: The Tokyo Metropolitan Government (TMG) conducted an external quality assessment (EQA) survey of pathogen nucleic acid amplification tests (NAATs) as a TMG EQA program for SARS-CoV-2 for clinical laboratories in Tokyo. METHODS: We diluted and prepared a standard product manufactured by...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishii, Yoshikazu, Aoki, Kotaro, Oda, Mayuko, Ichikawa, Megumi, Moriuchi, Rie, Konishi, Hiroyuki, Nagashima, Mami, Sadamasu, Kenji, Sugishita, Yoshiyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577997/
https://www.ncbi.nlm.nih.gov/pubmed/34776346
http://dx.doi.org/10.1016/j.jiac.2021.10.027
_version_ 1784596180540325888
author Ishii, Yoshikazu
Aoki, Kotaro
Oda, Mayuko
Ichikawa, Megumi
Moriuchi, Rie
Konishi, Hiroyuki
Nagashima, Mami
Sadamasu, Kenji
Sugishita, Yoshiyuki
author_facet Ishii, Yoshikazu
Aoki, Kotaro
Oda, Mayuko
Ichikawa, Megumi
Moriuchi, Rie
Konishi, Hiroyuki
Nagashima, Mami
Sadamasu, Kenji
Sugishita, Yoshiyuki
author_sort Ishii, Yoshikazu
collection PubMed
description INTRODUCTION: The Tokyo Metropolitan Government (TMG) conducted an external quality assessment (EQA) survey of pathogen nucleic acid amplification tests (NAATs) as a TMG EQA program for SARS-CoV-2 for clinical laboratories in Tokyo. METHODS: We diluted and prepared a standard product manufactured by Company A to about 2,500 copies/mL to make a positive control and distribute it with a negative control. The participants reported the use of the NAATs methods for SARS-CoV-2, the name of the real-time RT-PCR kit, the name of the detection device, the target gene(s), nucleic acid extraction kit, Threshold Cycle value in the case of RT-PCR and the Threshold time value and Differential calculation value in the case of Loop-Mediated Isothermal Amplification (LAMP) method. RESULTS: As a result, 17 laboratories using fully automated equipment and 34 laboratories using the RT-PCR method reported generally appropriate results in this EQA survey. On the other hand, among the laboratories that adopted the LAMP method, there were a plurality of laboratories that judged positive samples to be negative. CONCLUSION: The false negative result is considered to be due to the fact that the amount of virus genome contained in the quality control reagent used this time was below the detection limit of the LAMP method combined with the rapid extraction reagent for influenza virus. On the other hand, false positive results are considered to be due to the non-specific reaction of the NAATs. The EQA program must be continued for the proper implementation of the pathogen NAATs.
format Online
Article
Text
id pubmed-8577997
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-85779972021-11-10 A study of quality assessment in SARS-CoV-2 pathogen nucleic acid amplification tests performance; from the results of external quality assessment survey of clinical laboratories in the Tokyo Metropolitan Government external quality assessment program in 2020 Ishii, Yoshikazu Aoki, Kotaro Oda, Mayuko Ichikawa, Megumi Moriuchi, Rie Konishi, Hiroyuki Nagashima, Mami Sadamasu, Kenji Sugishita, Yoshiyuki J Infect Chemother Original Article INTRODUCTION: The Tokyo Metropolitan Government (TMG) conducted an external quality assessment (EQA) survey of pathogen nucleic acid amplification tests (NAATs) as a TMG EQA program for SARS-CoV-2 for clinical laboratories in Tokyo. METHODS: We diluted and prepared a standard product manufactured by Company A to about 2,500 copies/mL to make a positive control and distribute it with a negative control. The participants reported the use of the NAATs methods for SARS-CoV-2, the name of the real-time RT-PCR kit, the name of the detection device, the target gene(s), nucleic acid extraction kit, Threshold Cycle value in the case of RT-PCR and the Threshold time value and Differential calculation value in the case of Loop-Mediated Isothermal Amplification (LAMP) method. RESULTS: As a result, 17 laboratories using fully automated equipment and 34 laboratories using the RT-PCR method reported generally appropriate results in this EQA survey. On the other hand, among the laboratories that adopted the LAMP method, there were a plurality of laboratories that judged positive samples to be negative. CONCLUSION: The false negative result is considered to be due to the fact that the amount of virus genome contained in the quality control reagent used this time was below the detection limit of the LAMP method combined with the rapid extraction reagent for influenza virus. On the other hand, false positive results are considered to be due to the non-specific reaction of the NAATs. The EQA program must be continued for the proper implementation of the pathogen NAATs. Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2022-02 2021-11-10 /pmc/articles/PMC8577997/ /pubmed/34776346 http://dx.doi.org/10.1016/j.jiac.2021.10.027 Text en © 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Original Article
Ishii, Yoshikazu
Aoki, Kotaro
Oda, Mayuko
Ichikawa, Megumi
Moriuchi, Rie
Konishi, Hiroyuki
Nagashima, Mami
Sadamasu, Kenji
Sugishita, Yoshiyuki
A study of quality assessment in SARS-CoV-2 pathogen nucleic acid amplification tests performance; from the results of external quality assessment survey of clinical laboratories in the Tokyo Metropolitan Government external quality assessment program in 2020
title A study of quality assessment in SARS-CoV-2 pathogen nucleic acid amplification tests performance; from the results of external quality assessment survey of clinical laboratories in the Tokyo Metropolitan Government external quality assessment program in 2020
title_full A study of quality assessment in SARS-CoV-2 pathogen nucleic acid amplification tests performance; from the results of external quality assessment survey of clinical laboratories in the Tokyo Metropolitan Government external quality assessment program in 2020
title_fullStr A study of quality assessment in SARS-CoV-2 pathogen nucleic acid amplification tests performance; from the results of external quality assessment survey of clinical laboratories in the Tokyo Metropolitan Government external quality assessment program in 2020
title_full_unstemmed A study of quality assessment in SARS-CoV-2 pathogen nucleic acid amplification tests performance; from the results of external quality assessment survey of clinical laboratories in the Tokyo Metropolitan Government external quality assessment program in 2020
title_short A study of quality assessment in SARS-CoV-2 pathogen nucleic acid amplification tests performance; from the results of external quality assessment survey of clinical laboratories in the Tokyo Metropolitan Government external quality assessment program in 2020
title_sort study of quality assessment in sars-cov-2 pathogen nucleic acid amplification tests performance; from the results of external quality assessment survey of clinical laboratories in the tokyo metropolitan government external quality assessment program in 2020
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577997/
https://www.ncbi.nlm.nih.gov/pubmed/34776346
http://dx.doi.org/10.1016/j.jiac.2021.10.027
work_keys_str_mv AT ishiiyoshikazu astudyofqualityassessmentinsarscov2pathogennucleicacidamplificationtestsperformancefromtheresultsofexternalqualityassessmentsurveyofclinicallaboratoriesinthetokyometropolitangovernmentexternalqualityassessmentprogramin2020
AT aokikotaro astudyofqualityassessmentinsarscov2pathogennucleicacidamplificationtestsperformancefromtheresultsofexternalqualityassessmentsurveyofclinicallaboratoriesinthetokyometropolitangovernmentexternalqualityassessmentprogramin2020
AT odamayuko astudyofqualityassessmentinsarscov2pathogennucleicacidamplificationtestsperformancefromtheresultsofexternalqualityassessmentsurveyofclinicallaboratoriesinthetokyometropolitangovernmentexternalqualityassessmentprogramin2020
AT ichikawamegumi astudyofqualityassessmentinsarscov2pathogennucleicacidamplificationtestsperformancefromtheresultsofexternalqualityassessmentsurveyofclinicallaboratoriesinthetokyometropolitangovernmentexternalqualityassessmentprogramin2020
AT moriuchirie astudyofqualityassessmentinsarscov2pathogennucleicacidamplificationtestsperformancefromtheresultsofexternalqualityassessmentsurveyofclinicallaboratoriesinthetokyometropolitangovernmentexternalqualityassessmentprogramin2020
AT konishihiroyuki astudyofqualityassessmentinsarscov2pathogennucleicacidamplificationtestsperformancefromtheresultsofexternalqualityassessmentsurveyofclinicallaboratoriesinthetokyometropolitangovernmentexternalqualityassessmentprogramin2020
AT nagashimamami astudyofqualityassessmentinsarscov2pathogennucleicacidamplificationtestsperformancefromtheresultsofexternalqualityassessmentsurveyofclinicallaboratoriesinthetokyometropolitangovernmentexternalqualityassessmentprogramin2020
AT sadamasukenji astudyofqualityassessmentinsarscov2pathogennucleicacidamplificationtestsperformancefromtheresultsofexternalqualityassessmentsurveyofclinicallaboratoriesinthetokyometropolitangovernmentexternalqualityassessmentprogramin2020
AT sugishitayoshiyuki astudyofqualityassessmentinsarscov2pathogennucleicacidamplificationtestsperformancefromtheresultsofexternalqualityassessmentsurveyofclinicallaboratoriesinthetokyometropolitangovernmentexternalqualityassessmentprogramin2020
AT ishiiyoshikazu studyofqualityassessmentinsarscov2pathogennucleicacidamplificationtestsperformancefromtheresultsofexternalqualityassessmentsurveyofclinicallaboratoriesinthetokyometropolitangovernmentexternalqualityassessmentprogramin2020
AT aokikotaro studyofqualityassessmentinsarscov2pathogennucleicacidamplificationtestsperformancefromtheresultsofexternalqualityassessmentsurveyofclinicallaboratoriesinthetokyometropolitangovernmentexternalqualityassessmentprogramin2020
AT odamayuko studyofqualityassessmentinsarscov2pathogennucleicacidamplificationtestsperformancefromtheresultsofexternalqualityassessmentsurveyofclinicallaboratoriesinthetokyometropolitangovernmentexternalqualityassessmentprogramin2020
AT ichikawamegumi studyofqualityassessmentinsarscov2pathogennucleicacidamplificationtestsperformancefromtheresultsofexternalqualityassessmentsurveyofclinicallaboratoriesinthetokyometropolitangovernmentexternalqualityassessmentprogramin2020
AT moriuchirie studyofqualityassessmentinsarscov2pathogennucleicacidamplificationtestsperformancefromtheresultsofexternalqualityassessmentsurveyofclinicallaboratoriesinthetokyometropolitangovernmentexternalqualityassessmentprogramin2020
AT konishihiroyuki studyofqualityassessmentinsarscov2pathogennucleicacidamplificationtestsperformancefromtheresultsofexternalqualityassessmentsurveyofclinicallaboratoriesinthetokyometropolitangovernmentexternalqualityassessmentprogramin2020
AT nagashimamami studyofqualityassessmentinsarscov2pathogennucleicacidamplificationtestsperformancefromtheresultsofexternalqualityassessmentsurveyofclinicallaboratoriesinthetokyometropolitangovernmentexternalqualityassessmentprogramin2020
AT sadamasukenji studyofqualityassessmentinsarscov2pathogennucleicacidamplificationtestsperformancefromtheresultsofexternalqualityassessmentsurveyofclinicallaboratoriesinthetokyometropolitangovernmentexternalqualityassessmentprogramin2020
AT sugishitayoshiyuki studyofqualityassessmentinsarscov2pathogennucleicacidamplificationtestsperformancefromtheresultsofexternalqualityassessmentsurveyofclinicallaboratoriesinthetokyometropolitangovernmentexternalqualityassessmentprogramin2020